Pacira BioSciences Inc’s filing revealed that its Director Ceesay Abraham unloaded Company’s shares for reported $64005.0 on Sep 04 ’25. In the deal valued at $27.19 per share,2,354 shares were sold. As a result of this transaction, Ceesay Abraham now holds 9,039 shares worth roughly $0.24 million.
Then, Ceesay Abraham bought 2,354 shares, generating $64,005 in total proceeds.
Before that, BIGAL MARCELO sold 4,912 shares. Pacira BioSciences Inc shares valued at $116,267 were divested by the Director at a price of $23.67 per share. As a result of the transaction, BIGAL MARCELO now holds 11,393 shares, worth roughly $0.3 million.
Truist upgraded its Pacira BioSciences Inc [PCRX] rating to a Buy from a a Hold in a research note published recently. A number of analysts have revised their coverage, including Truist’s analysts, who increased its forecast for the stock in late January from “a Sell” to “a Hold”. Truist also remained covering PCRX and has decreased its forecast on August 13, 2024 with a “Sell” recommendation from previously “Buy” rating. RBC Capital Mkts revised its rating on August 12, 2024. It rated PCRX as “a Sector perform” which previously was an “an Outperform”.
Price Performance Review of PCRX
On Friday, Pacira BioSciences Inc [NASDAQ:PCRX] saw its stock jump 0.04% to $26.66. Over the last five days, the stock has lost -1.70%. Pacira BioSciences Inc shares have risen nearly 85.85% since the year began. Nevertheless, the stocks have risen 41.51% over the past one year.
How much short interest is there in Pacira BioSciences Inc?
A steep rise in short interest was recorded in Pacira BioSciences Inc stocks on 2025-08-29, growing by 0.91 million shares to a total of 6.61 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 5.69 million shares. There was a rise of 13.83%, which implies that there is a positive sentiment for the stock.
